- Leqembi posts $184M Q2 sales, best quarter since launch, Biogen lifts guidanceLeqembi, the anti-amyloid Alzheimer’s drug co-developed by Eisai and Biogen, generated $184 million in global sales in the second quarter, according to Biogen. The Q2 figure represents the stronge…
- Boston Scientific unveils major restructuring, plots job cuts amid savings driveMedical device maker Boston Scientific has been a prolific dealmaker this year but is now taking a step back as it looks to make changes internally.